BackgroundCurrent therapies have succeeded in controlling AIDS pandemic. However, there is a continuing need for new drugs, in particular those acting through new and as yet unexplored mechanisms of action to achieve HIV infection cure. We took advantage of the unique feature of proviral genome to require both activation and inhibition of splicing of viral transcripts to develop molecules capable of achieving long lasting effect on viral replication in humanized mouse models through inhibition of Rev-mediated viral RNA biogenesis.ResultsCurrent HIV therapies reduce viral load during treatment but titers rebound after treatment is discontinued. We devised a new drug that has a long lasting effect after viral load reduction. We demonstrate here that ABX464 compromises HIV replication of clinical isolates of different subtypes without selecting for drug resistance in PBMCs or macrophages. ABX464 alone, also efficiently compromised viral proliferation in two humanized mouse models infected with HIV that require a combination of 3TC, Raltegravir and Tenofovir (HAART) to achieve viral inhibition in current protocols. Crucially, while viral load increased dramatically just one week after stopping HAART treatment, only slight rebound was observed following treatment cessation with ABX464 and the magnitude of the rebound was maintained below to that of HAART for two months after stopping the treatment. Using a system to visualize single HIV RNA molecules in living cells, we show that ABX464 inhibits viral replication by preventing Rev-mediated export of unspliced HIV-1 transcripts to the cytoplasm and by interacting with the Cap Binding Complex (CBC). Deep sequencing of viral RNA from treated cells established that retained viral RNA is massively spliced but importantly, normal cellular splicing is unaffected by the drug. Consistently ABX464 is non-toxic in humans and therefore represents a promising complement to current HIV therapies.ConclusionsABX464 represents a novel class of anti-HIV molecules with unique properties. ABX464 has a long lasting effect in humanized mice and neutralizes the expression of HIV-1 proviral genome of infected immune cells including reservoirs and it is therefore a promising drug toward a functional cure of HIV.Electronic supplementary materialThe online version of this article (doi:10.1186/s12977-015-0159-3) contains supplementary material, which is available to authorized users.

Polystyrene-poly(ethylene glycol) resin-captured cross-linked palladium nanopaticles were prepared via a straightforward route, and their heterogeneous behavior was truly confirmed by various tests. They were applied to aqueous Suzuki cross-coupling reactions with various aryl bromides and recycled up to six times without loss of activity.

Palladium nanoparticles were entrapped within resin plugs and used in a range of ligand-free cross-coupling reactions; the convenient modular format of the resin plug enhanced resin handling and allowed the catalysts to be easily recovered and multiply reused.

Captured and Cross-Linked Palladium Nanoparticles. -Cross-linked resin-captured palladium (XL-RC Pd) catalyzes a series of solution-phase aqueous Suzuki coupling reactions of aryl bromides to give the desired biaryls (III). Aryl chlorides such as (Ie) afford only low yields. Conducting the reactions under microwave irradiation reduces the reaction time to 10 min. The XL-RC Pd catalyst can be recycled six times without loss of catalytic activity and applied to the synthesis of sulfophthalein dyes such as (IIIf). -(CHO, J. K.; NAJMAN, R.; DEAN, T. W.; ICHIHARA, O.; MULLER, C.; BRADLEY*, M.; J.

Targeting SRSF1 with ABX300 compensates for changes in RNA biogenesis induced by fat accumulation and consequently represents a novel unexplored approach for the treatment of obesity.

Compounds belonging to the 5-acyl-3,4-dihydropyrimidine-2-thione family were obtained using a solvent-free Biginelli condensation with or without the use of a catalyst. An unprecedented solid-phase procedure involving a polymer-supported aldehyde allowed the preparation of a series of 5-aroyl derivatives starting with crude diketones obtained from their corresponding aryl esters.

ChemInform is a weekly Abstracting Service, delivering concise information at a glance that was extracted from about 200 leading journals. To access a ChemInform Abstract of an article which was published elsewhere, please select a “Full Text” option. The original article is trackable via the “References” option.

Procedures. -The title compounds (IV) are synthesized using a solvent-free solution phase Biginelli condensation reaction. An analogous protocol involving polymer-supported m-hydroxybenzaldehyde gives only low yields (10-15%) of dihydropyrimidine-2-thiones. -(COMAS, H.; BUISSON, D.-A.; NAJMAN, R.; KOZIELSKI, F.; ROUSSEAU, B.; LOPEZ*, R.; Synlett 2009, 11, 1737-1740; Commis. Energ. At., Dep. Bioorg. Chem., CEA, F-91191 Gif-sur-Yvette, Fr.; Eng.) -Mais 49-166